Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your Favored Pizza Cover - 2Clovis Unified students spend spring break traveling through China
- 3RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- 4‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- 56 Web-based Lawful Administrations: Extensive Surveys and Elements
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- These Cities Led Global Jet-Setting In 2025, According To New Data
- How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Nvidia Share Price Could Be Hit Hard By Iran War
- Turkey, Egypt, Qatar discuss second phase of Gaza ceasefire deal
- All that You Really want to Be familiar with Dental Inserts Facilities
- Investigating Remarkable Espresso Flavors: Upgrade Your Day to day Blend
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
